foslinanib   Click here for help

GtoPdb Ligand ID: 11621

Synonyms: CVM-1118 | TRX 818 | TRX-818
Compound class: Synthetic organic
Comment: Foslinanib (CVM-1118) is an orally bioavailable protein kinase inhibitor with antiangiogenic and antineoplastic activities [1].
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 3
Hydrogen bond donors 3
Rotatable bonds 4
Topological polar surface area 118.66
Molecular weight 365.05
XLogP 2.73
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES COc1ccc2c(c1OP(=O)(O)O)c(=O)cc([nH]2)c1cccc(c1)F
Isomeric SMILES COc1ccc2c(c1OP(=O)(O)O)c(=O)cc([nH]2)c1cccc(c1)F
InChI InChI=1S/C16H13FNO6P/c1-23-14-6-5-11-15(16(14)24-25(20,21)22)13(19)8-12(18-11)9-3-2-4-10(17)7-9/h2-8H,1H3,(H,18,19)(H2,20,21,22)
InChI Key ZDWFMAHQGDEALT-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
Foslinanib (CVM-1118) has advanced to phase 2 clinical evaluation in oncology indications.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03582618 CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma Phase 2 Interventional TaiRx, Inc.
NCT03600233 Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors Phase 2 Interventional TaiRx, Inc.
NCT04336124 Safety and Pharmacokinetic Study of CVM-1118 Extended-Release in Advanced Cancer Patients Phase 1 Interventional TaiRx, Inc.